Aptorum Group Limited/$APM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
Ticker
$APM
Sector
Primary listing
Employees
1
Headquarters
Website
APM Metrics
BasicAdvanced
$7.1m
-
-$0.19
-0.01
-
Price and volume
Market cap
$7.1m
Beta
-0.01
52-week high
$4.47
52-week low
$0.65
Average daily volume
74k
Financial strength
Current ratio
0.782
Quick ratio
0.752
Total debt to equity
25.049
Interest coverage (TTM)
-18.99%
Profitability
EBITDA (TTM)
-1.562
Management effectiveness
Return on assets (TTM)
-6.52%
Return on equity (TTM)
-10.79%
Valuation
Price to book
0.31
Price to tangible book (TTM)
0.31
Price to free cash flow (TTM)
-3.503
Free cash flow yield (TTM)
-28.55%
Free cash flow per share (TTM)
-0.25
Growth
Earnings per share change (TTM)
-76.31%
3-year earnings per share growth (CAGR)
-59.30%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aptorum Group Limited stock?
Aptorum Group Limited (APM) has a market cap of $7.1M as of May 04, 2026.
What is the P/E ratio for Aptorum Group Limited stock?
The price to earnings (P/E) ratio for Aptorum Group Limited (APM) stock is 0 as of May 04, 2026.
Does Aptorum Group Limited stock pay dividends?
No, Aptorum Group Limited (APM) stock does not pay dividends to its shareholders as of May 04, 2026.
When is the next Aptorum Group Limited dividend payment date?
Aptorum Group Limited (APM) stock does not pay dividends to its shareholders.
What is the beta indicator for Aptorum Group Limited?
Aptorum Group Limited (APM) has a beta rating of -0.01. This means that it has an inverse relation to market volatility.